The FDA has approved Triesence, Alcon's preservative-free synthetic coricosteroid for visualization during vitrectomy.
The FDA has approved Triesence, Alcon's preservative-free synthetic coricosteroid for visualization during vitrectomy.
Triesence injectable suspension, the active ingredient of which is triamcinolone acetonide, is indicated for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids, in addition to being used for visualization during vitrectomy.
23rd annual EURETINA Congress: seeing eye to eye in Amsterdam
September 25th 2023Experts in all aspects of retinal care will gather at the RAI Amsterdam Convention Centre, located in the Zuidas business district of the city, which is a short distance from historic Amsterdam with is canals, museums, and shops
2 Clarke Drive
Cranbury, NJ 08512